Stonegate Capital Partners Initiates Coverage on GoHealth Inc. (GOCO)
GoHealth Inc. (NASDAQ: GOCO) demonstrated robust performance in Q4 2024, with net revenues climbing 41% year-over-year to $389.1 million. The company's success was driven by a significant 67% increase in submissions, while achieving operational efficiencies with a 27% improvement in Direct Operating Cost per Submission to $501.
The Medicare-focused digital health marketplace provider reported a remarkable turnaround, posting a net income of $58.0 million, compared to a loss in the previous year. Additionally, the company's Adjusted EBITDA more than doubled to $117.8 million, reflecting successful strategic investments in technology and operational excellence.
GoHealth Inc. (NASDAQ: GOCO) ha dimostrato una performance robusta nel Q4 2024, con ricavi netti in aumento del 41% anno su anno, raggiungendo i 389,1 milioni di dollari. Il successo dell'azienda è stato guidato da un aumento significativo del 67% nelle sottomissioni, mentre ha raggiunto efficienze operative con un miglioramento del 27% nei Costi Operativi Diretti per Sottomissione, pari a 501 dollari.
Il fornitore di un marketplace digitale per la salute focalizzato su Medicare ha registrato un notevole cambiamento di rotta, con un reddito netto di 58,0 milioni di dollari, rispetto a una perdita nell'anno precedente. Inoltre, l'EBITDA Adjusted dell'azienda è più che raddoppiato, raggiungendo i 117,8 milioni di dollari, riflettendo investimenti strategici di successo in tecnologia ed eccellenza operativa.
GoHealth Inc. (NASDAQ: GOCO) demostró un rendimiento robusto en el Q4 de 2024, con ingresos netos que aumentaron un 41% interanual, alcanzando los 389.1 millones de dólares. El éxito de la empresa fue impulsado por un aumento significativo del 67% en las presentaciones, logrando al mismo tiempo eficiencias operativas con una mejora del 27% en el Costo Operativo Directo por Presentación, que se situó en 501 dólares.
El proveedor de un mercado digital de salud enfocado en Medicare reportó un notable cambio de rumbo, publicando un ingreso neto de 58.0 millones de dólares, en comparación con una pérdida en el año anterior. Además, el EBITDA Ajustado de la empresa se más que duplicó, alcanzando los 117.8 millones de dólares, reflejando inversiones estratégicas exitosas en tecnología y excelencia operativa.
GoHealth Inc. (NASDAQ: GOCO)는 2024년 4분기에 강력한 실적을 보여주었으며, 연간 41% 증가한 3억 8,910만 달러의 순수익을 기록했습니다. 회사의 성공은 제출 건수가 67% 증가한 것에 의해 이끌어졌으며, 제출당 직접 운영 비용이 501달러로 27% 개선되는 운영 효율성을 달성했습니다.
메디케어 중심의 디지털 건강 시장 제공업체는 놀라운 전환을 보고하며, 5800만 달러의 순이익을 기록했으며, 이는 전년도 손실과 비교됩니다. 또한, 회사의 조정 EBITDA는 두 배 이상 증가하여 1억 1,780만 달러에 달했습니다, 이는 기술 및 운영 우수성에 대한 성공적인 전략적 투자를 반영합니다.
GoHealth Inc. (NASDAQ: GOCO) a montré une performance robuste au T4 2024, avec des revenus nets en hausse de 41 % d'une année sur l'autre, atteignant 389,1 millions de dollars. Le succès de l'entreprise a été soutenu par une augmentation significative de 67 % des soumissions, tout en atteignant des efficacités opérationnelles avec une amélioration de 27 % du Coût d'Exploitation Direct par Soumission à 501 dollars.
Le fournisseur de marché de la santé numérique axé sur Medicare a signalé un retournement remarquable, affichant un revenu net de 58,0 millions de dollars, par rapport à une perte l'année précédente. De plus, l'EBITDA Ajusté de l'entreprise a plus que doublé, atteignant 117,8 millions de dollars, reflétant des investissements stratégiques réussis dans la technologie et l'excellence opérationnelle.
GoHealth Inc. (NASDAQ: GOCO) zeigte im 4. Quartal 2024 eine robuste Leistung, mit netto Einnahmen, die im Jahresvergleich um 41% auf 389,1 Millionen Dollar stiegen. Der Erfolg des Unternehmens wurde durch einen signifikanten Anstieg der Einreichungen um 67% vorangetrieben, während operative Effizienzen mit einer Verbesserung der direkten Betriebskosten pro Einreichung um 27% auf 501 Dollar erzielt wurden.
Der Anbieter des digitalen Gesundheitsmarktplatzes, der sich auf Medicare konzentriert, berichtete von einer bemerkenswerten Wende und erzielte einen Nettoertrag von 58,0 Millionen Dollar, im Vergleich zu einem Verlust im Vorjahr. Darüber hinaus hat sich das bereinigte EBITDA des Unternehmens mehr als verdoppelt und beträgt nun 117,8 Millionen Dollar, was den Erfolg strategischer Investitionen in Technologie und operative Exzellenz widerspiegelt.
- Net revenues increased 41% YoY to $389.1M
- Achieved net income of $58.0M, turning around from previous year's loss
- Adjusted EBITDA more than doubled to $117.8M
- Submissions grew 67% YoY
- Direct Operating Cost per Submission reduced by 27% to $501
- None.
Dallas, Texas--(Newsfile Corp. - March 24, 2025) - GoHealth Inc. (NASDAQ: GOCO): Stonegate Capital Partners initiates their coverage on GoHealth Inc. (NASDAQ: GOCO). GoHealth, Inc. delivered a strong fourth quarter in 2024, highlighted by substantial revenue growth and operational efficiencies. Net revenues surged
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Net revenues surged
41% y/y to$389.1M . - Saw a
170% year-over-year increase in submissions. - Direct Operating Cost per Submission improved by
27% year-over-year to$501.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/245801
FAQ
What was GoHealth's (GOCO) revenue growth in Q4 2024?
How much did GoHealth (GOCO) improve its Direct Operating Cost per Submission in Q4 2024?
What was GoHealth's (GOCO) net income in Q4 2024?
How much did GoHealth's (GOCO) submissions increase in Q4 2024?
What was GoHealth's (GOCO) Adjusted EBITDA in Q4 2024?
